| Literature DB >> 27886086 |
Siling Bi1, Fuhao Chu2, Mina Wang3, Bi Li4, Pei Mao5, Huazheng Zhang6, Penglong Wang7, Wenbo Guo8, Liang Xu9, Liwei Ren10, Haimin Lei11, Yuzhong Zhang12.
Abstract
Hepatic fibrosis is a naturally occurring wound-healing reaction, with an imbalance of extracellular matrix (ECM) during tissue repair response, which can further deteriorate to hepatocellular carcinoma without timely treatment. Inhibiting activated hepatic stellate cell (HSC) proliferation and inducing apoptosis are the main methods for the treatment of liver fibrosis. In our previous study, we found that the TOA-glycine derivative (G-TOA) had exhibited more significant inhibitory activity against HepG2 cells and better hydrophilicity than TOA, ligustrazine (TMP), and oleanolic acid (OA). However, inhibiting activated HSC proliferation and inducing apoptosis by G-TOA had not been reported. In this paper, the selective cytotoxicity of G-TOA was evaluated on HSC-T6 cells and L02 cells, and apoptosis mechanisms were explored. It was found that G-TOA could selectively inhibit the proliferation of activated HSC-T6 cells, induce morphological changes, early apoptosis, and mitochondrial membrane potential depolarization, increase intracellular free calcium levels, downregulate the expression of NF-κB/p65 and COX-2 protein, and decrease the ratio of Bcl-2/Bax, thereby inducing HSC-T6 cell apoptosis. Thence, G-TOA might be a potential antifibrosis agent for the therapy of hepatic fibrosis, provided that it exerts anti-fibrosis effects on activated HSC-T6 cells.Entities:
Keywords: HSC-T6 cells; apoptosis; hepatic fibrosis; ligustrazine-oleanolic acid glycine derivative; selectively inhibition
Mesh:
Substances:
Year: 2016 PMID: 27886086 PMCID: PMC6273822 DOI: 10.3390/molecules21111599
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The effect of the TOA-glycine derivative (G-TOA) and colchicine on the proliferation of HSC-T6 cells and L02 cells. (a) The effect of G-TOA and colchicine on the proliferation of HSC-T6 cells; (b) The effect of G-TOA on the proliferation of HSC-T6 cells and L02 cells were determined for 48 h. Compared with the normal control group. * p < 0.05; ** p < 0.01.
Figure 2The effect of G-TOA on the morphology of HSC-T6 cells.
Figure 3The effect of G-TOA on the nuclear fragmentation of HSC-T6 cells.
Figure 4(a) The effect of different concentrations of G-TOA on the apoptosis of HSC-T6 cells; (b) Apoptosis ratios (including the early and late apoptosis ratios) on different concentrations of administration. Compared with the control group. ** p < 0.01.
Figure 5(a) The effect of different concentrations of G-TOA on the cell cycle of HSC-T6 cells; (b) The ratios of different phases of cell cycle on different concentrations of administration.
Figure 6(a) The effect of different concentrations of G-TOA on the mitochondrial membrane potential of HSC-T6 cells. (b) The green ratios on different concentrations of administration. Compared with the control group. * p < 0.05; ** p < 0.01.
Figure 7The effect of G-TOA on the free calcium level of HSC-T6 cells. Compared with the control group; ** p < 0.01.
Figure 8(a) The effect of G-TOA on the expression of NF-κB/p65 protein in HSC-T6 cells; (b) The effect of G-TOA on the expression of COX-2 protein in HSC-T6 cells.
Figure 9The effect of G-TOA on the expression of Bcl-2 and Bax protein (a) and the ratio of Bcl-2/Bax of HSC-T6 cells (b) Comparison with the normal control group. * p < 0.05; ** p < 0.01.